Matrix Metalloproteinases in Non-Neoplastic Disorders
AbstractThe matrix metalloproteinases (MMPs) are zinc-dependent endopeptidases belonging to the metzincin superfamily. There are at least 23 members of MMPs ever reported in human, and they and their substrates are widely expressed in many tissues. Recent growing evidence has established that MMP not only can degrade a variety of components of extracellular matrix, but also can cleave and activate various non-matrix proteins, including cytokines, chemokines and growth factors, contributing to both physiological and pathological processes. In normal conditions, MMP expression and activity are tightly regulated via interactions between their activators and inhibitors. Imbalance among these factors, however, results in dysregulated MMP activity, which causes tissue destruction and functional alteration or local inflammation, leading to the development of diverse diseases, such as cardiovascular disease, arthritis, neurodegenerative disease, as well as cancer. This article focuses on the accumulated evidence supporting a wide range of roles of MMPs in various non-neoplastic diseases and provides an outlook on the therapeutic potential of inhibiting MMP action. View Full-Text
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Tokito, A.; Jougasaki, M. Matrix Metalloproteinases in Non-Neoplastic Disorders. Int. J. Mol. Sci. 2016, 17, 1178.
Tokito A, Jougasaki M. Matrix Metalloproteinases in Non-Neoplastic Disorders. International Journal of Molecular Sciences. 2016; 17(7):1178.Chicago/Turabian Style
Tokito, Akinori; Jougasaki, Michihisa. 2016. "Matrix Metalloproteinases in Non-Neoplastic Disorders." Int. J. Mol. Sci. 17, no. 7: 1178.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.